assessed in human blood left at room temperature or at 4°C. Ketamine, NK, and DHNK at a concentration of 500 g/L were added to blood samples from volunteers. The samples were divided into two aliquots: one was stored at room temperature (ϳ20°C) and the other at 4°C. At t 0 and at 30, 60, and 120 min, 8 mL of each aliquot was removed and immediately centrifuged at 2000g for 10 min at 20°C. The plasma was decanted and stored immediately at Ϫ20°C until analysis. The assay was performed within 15 days of storage, and five replicates were used in each case. Results were compared using the nonparametric Mann-Whitney test. Two-tailed values Ͻ0.05 were considered significant. Statistical analysis was performed using Graphpad Instat software.
served in the concentrations of ketamine and its metabolites in human serum left at 4°C for 2 days. Storage of ketamine, NK, and DHNK in human serum at Ϫ20°C did not produce significant changes in concentrations over a period of 10 weeks. These data are in accordance with those reported previously (7 ) . As shown in Table 1 , plasma concentrations of ketamine and NK remained constant when the centrifugation of blood was delayed for 2 h, and the stability of the two compounds was not affected by the change in storage temperature from 4 to 20°C. On the other hand, a significant decrease in the plasma DHNK concentration was observed when blood samples were kept at 4°C, whereas surprisingly, the DHNK concentration did not change significantly when blood samples were left for 2 h at room temperature.
After 30 min of storage at 4°C, the plasma concentration of DHNK was, on average, 68% of the initial concentration. Furthermore, we also observed that the plasma concentrations of DHNK measured at t 0 represented, on average, only 75% of the concentration added to blood and stored at 4°C or at room temperature. These results could suggest that DHNK is unequally distributed between plasma and blood cells and that rapid permeation of this compound into blood cells may occur. Chemical degradation is not likely because the increase in temperature from 4 to 20°C slowed the decrease in DHNK concentrations. Further investigations should be done to study the effect of various temperatures on the plasma concentration of DHNK. Moreover, the determination of DHNK concentrations in blood cells to estimate the partitioning behavior of this compound may be warranted.
In conclusion, the present study shows the necessity of observing rigorous conditions for the accurate estimation of ketamine metabolite concentrations in blood samples. The collected blood should be centrifuged without delay at ambient temperature to avoid the decrease in DHNK concentrations, which is most likely attributable to the permeation of this compound into the blood cells. The plasma samples can be transported at 4°C within 2 days and can be stored at Ϫ20°C for 10 weeks without any change in the concentrations of ketamine, NK, and DHNK.
␤-Core fragment (␤cf) is the main metabolic breakdown product of human chorionic gonadotropin (hCG) (1 ) . This analyte appears in maternal urine during pregnancy, but is undetectable in serum. Recent studies (2) (3) (4) have shown that concentrations of hCG␤cf are substantially increased in pregnancies affected by Down syndrome, suggesting the use of this analyte for midtrimester antenatal screening. However, various groups of investigators have reported large differences in the efficacy of screening by means of hCG␤cf (5) (6) (7) . Some of these inconsistencies have been attributed to conditions used for storage of urine specimens (8 ) , as well as chance, assay method, and study design (7 ) .
hCG serum concentrations show distinct diurnal variation (9 ) . We investigated whether urine concentrations of hCG␤cf, the terminal breakdown product of serum hCG, also show diurnal variation. Alterations in the time of day when urine specimens were collected in previously reported studies could potentially explain the inconsistent findings on the screening efficacy of this analyte for Down syndrome. We prospectively and longitudinally examined hCG␤cf concentrations in urine from women with uncomplicated midtrimester pregnancies.
We prospectively studied 46 healthy pregnant women at 15-19 weeks of gestation. Pregnancies were dated by menstrual history and first-trimester ultrasonographic examination and followed until delivery. A detailed history was obtained from all volunteers to exclude preexisting medical or obstetric complications.
Midstream urine samples were collected at 0600, 1200, 1800, and 0000. Specimens were frozen within 4 h and stored at Ϫ20°C until assayed for hCG␤cf within 7 days of collection. hCG␤cf concentrations were measured by use of a commercially available enzyme-immunoassay reagent set (Novamed Ltd.). The test was repeated at a different dilution if the measured concentration was outside the operating range. Measurements of hCG␤cf were indexed to urine creatinine concentrations, as measured by an enzymatic creatinine assay. Fetal karyotypes obtained by amniocentesis were available for 14 participants and were normal. Fetuses without available karyotypes were normal at birth. Normalized hCG␤cf concentrations were also expressed as multiples of the smoothed medians (MoMs) for the duration of gestation. Medians for the duration of gestation (per week) were obtained from the analysis of 674 urine specimens from pregnant women (15-19 weeks gestation) by use of the same laboratory methods. For these specimens, no attention was paid to the time of day of collection.
Ratios of urine hCG␤cf/urine creatinine concentrations were statistically analyzed by one-way ANOVA (SPSS, Ver. 8.00) after natural log transformation. P Ͻ0.005 was defined as statistically significant.
Mean maternal age and gestational age in the study group were 29.8 years (SD, 3.94; range, 19 -35 years) and 17.2 weeks (SD, 1.41 weeks; range, 15-20 weeks), respectively. Mean gravidity and parity were 1.82 (SD, 1.01; range, 1-5) and 0.56 (SD, 0.94; range, 0 -4), respectively. Mean maternal weight was 58.3 Ϯ 6.5 kg (range, 47-85). Measurements of hCG␤cf and creatinine at the various sampling times are reported in Table 1 . Crude hCG␤cf concentrations varied significantly during the day, with peak concentrations occurring at 0600 and the lowest concentrations at 1800; mean differences in measured concentrations were 225%. Creatinine concentrations also showed distinct diurnal variation, with concentrations highest at 0600 and lowest at 1200. Creatinine concentrations were used to normalize hCG␤cf concentrations in urine specimens ( Table 1 ). The mean difference between creatinine-normalized peak and nadir urine hCG␤cf concentrations was 211%. When hCG␤cf/creatinine ratios were expressed as MoMs for 1 week of gestation, the difference between median peak and nadir concentrations was 0.8 MoM. Normalized hCG␤cf concentrations were highest at 0600 and lowest at 1800 (Fig. 1) ; ANOVA showed that the difference was statistically significant (P Ͻ0.0001). Compared with baseline values at 0, concentrations were significantly different at 0600 (P Ͻ0.005) and 1200 (P Ͻ0.005).
The main finding of our study was that creatininenormalized hCG␤cf concentrations in urine showed significant diurnal variation. The difference between peak and nadir concentrations was equivalent to 0.8 MoM. One would expect, therefore, that calculations of the risk of Down syndrome must be substantially affected by the timing of urine specimen collection. In turn, these findings could explain some of the reported inconsistencies in reported screening efficacies.
Urine hCG␤cf is the final metabolic breakdown product of the nicked hCG ␤ subunit. Increased nicking of the ␤ subunit in Down syndrome pregnancies was first demonstrated by Rotmensch and coworkers (10, 11 ) , but the mechanism for this phenomenon remains unclear. Greater phagocytic activity against the placenta as a foreign semiallograft for the mother and increased nicking activity in the sera of pregnant women have been proposed.
Early studies found urine concentrations of hCG␤cf to be five-to sixfold higher in Down syndrome than in normal pregnancies (12 ) . However, as more studies have been published, the early results have been at the high end of the range. In fact, the variability of results has been unusually great; concentrations of hCG␤cf between 1.3and 6.1-fold higher than the unaffected median have been reported (12 ) . This variability suggests that factors other than the biology of Down syndrome pregnancies affect the results. It is unclear, at present, whether dividing hCG␤cf concentrations by creatinine concentrations properly normalizes for sample concentrations (13 ) . It is conceivable that in very dilute urine, the relationship between creatinine and urine concentrations of hCG␤cf is altered. Cole et al. (8 ) showed that urine concentrations of hCG␤cf in Down syndrome pregnancies decrease over time in storage, possibly because of aggregation. This finding implied that the interval between sampling of urine and the assay could substantially affect hCG␤cf concentrations. Cuckle et al. (7 ) considered the possibility that hCG␤cf concentrations in urine may vary during the day, even after normalization with creatinine. As part of a large multicenter study on the screening efficacy of hCG␤cf for Down syndrome, cross-sectional information on the time of voiding was obtained toward the end of patient recruitment. The data showed an impressive increase in urine hCG␤cf concentrations, from 0.7 MoM at 0400 to 1.4 MoM at 0800. These findings appear to be consistent with our own data, showing a similar increase between 0000 and 0600. However, the study by Cuckle et al. (7 ) reported cross-sectional data between 0400 and 1600, whereas in our study, participants were followed up longitudinally for 24 h. Our findings make it plausible that diurnal variation in urine concentrations of hCG␤cf could affect the efficacy of screening for Down syndrome. On the one hand, there is no reason to believe that women with Down syndrome pregnancies and women with normal pregnancies have systematically collected samples at different times of the day in the previously reported studies. However, the number of Down syndrome pregnancies has been very small in most published studies. Therefore, we cannot exclude differences in timing of sampling for these few specimens, compared with the women with normal pregnancies, as a cause of the reported inconsistencies.
In summary, hCG␤cf displays substantial diurnal variation. Assessment of the value of hCG␤cf as a screening marker for Down syndrome should be reconsidered when data adjusted for time of sampling are available.
